Balancing Innovation: India’s Views for Pharmaceuticals in the Efta Trade Deal
IIPRD
APRIL 2, 2024
Here, developing a new medicine requires substantial investment which comes with a high degree of uncertainty. [iv] v] This, in turn, can lead to significant price hikes for essential medicines. The inclusion of TRIPS-plus provisions within trade agreements presents a potential challenge to global access to essential medicines.
Let's personalize your content